Loxapine succinate as a neuroleptic agent: evaluation in two populations of elderly psychiatric patients.
Loxapine succinate, a newly developed neuroleptic drug, was administered to two groups of geropsychiatric patients: (a) 12 with psychosis and organic brain syndrome, and (b) 14 with chronic schizophrenia. After a two-week baseline period, loxapine was given for 12 weeks. The moderate therapeutic effect of loxapine in the "responders" was similar to that of other neuroleptic drugs. The therapeutic dosage range was found to be from 10 to 80 mg daily--about half that used for younger patients. The chief side effects were drowsiness, mild extrapyramidal symptoms, and a slight increase in blood pressure.
D000368:Aged; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D005069:Evaluation Studies as Topic; D005260:Female; D006801:Humans; D008152:Loxapine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D008297:Male; D019965:Neurocognitive Disorders / Q000188:drug therapy*; D012559:Schizophrenia / Q000188:drug therapy*
D003989:Dibenzoxazepines; D008152:Loxapine